Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 77, Issue 19, 2011, Pages 1752-1755

  Zesiewicz, T A ^a   Elble, R J ^b   Louis, E D ^c   Gronseth, G S ^d   Ondo, W G ^e   Dewey Jr , R B ^f   Okun, M S ^g   Sullivan, K L ^a   Weiner, W J ^h  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF FLORIDA   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; ALPRAZOLAM; ATENOLOL; BOTULINUM TOXIN A; CLONAZEPAM; CLOZAPINE; ETIRACETAM; FLUNARIZINE; GABAPENTIN; NADOLOL; NIMODIPINE; OLANZAPINE; PLACEBO; PREGABALIN; PRIMIDONE; PROPRANOLOL; SOTALOL; TOPIRAMATE; ZONISAMIDE;

AKATHISIA; ARTICLE; BRAIN DEPTH STIMULATION; CINAHL; DIZZINESS; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EMBASE; ESSENTIAL TREMOR; EVIDENCE BASED PRACTICE; GAMMA KNIFE RADIOSURGERY; HUMAN; MEDLINE; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCISEARCH; SINGLE DRUG DOSE; THALAMOTOMY; TREATMENT OUTCOME;

EID: 82955243943     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318236f0fd     Document Type: Article

References (21)

1. Koller WC, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986;36:1001-1004. (Pubitemid 16098252)
2. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor: Ad Hoc Scientific Committee. Mov Disord 1998;13(suppl 3):2-23. (Pubitemid 28517753)
3. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39:1587-1588. (Pubitemid 20013592)
4. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64:2008-2020. (Pubitemid 40880986)
5. Ondo WG, Jankovic J, Connor GS, et al, Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006;66:672-677.
6. Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol 2008;31:97-103. (Pubitemid 351489336)
7. Yetimalar Y, Irtman G, Kurt T, Başoǧlu M. Olanzapine versus propranolol in essential tremor. Clin Neurol Neurosurg 2005;108:32-35. (Pubitemid 41727740)
8. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 2005;64:1078-1080. (Pubitemid 40388470)
9. Elble RJ, Lyons KE, Pahwa R. Levetiracetam is not effective for essential tremor. Clin Neuropharmacol 2007;30:350-356. (Pubitemid 350307314)
10. Handforth A, Martin FC. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. Mov Disord 2004;19:1215-1221. (Pubitemid 39429965)
11. Lorenz D, Hagen K, Ufer M, Cascorbi I, Deuschl G, Volkmann J. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study. Neurology 2006;66:1753-1755. (Pubitemid 43964639)
12. Vecchio I, Rampello L, Tornali C, Malaguarnera M, Raffaele R. Flunarizine and essential tremor in the elderly. Arch Gerontol Geriatr 1996;22(suppl 1):73-77.
13. Curran T, Lang AE. Flunarizine in essential tremor. Clin Neuropharmacol 1993;16:460-463. (Pubitemid 23292103)
14. Zesiewicz TA, Ward CL, Hauser RA, et al. A pilot, doubleblind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord 2007;22:1660-1663. (Pubitemid 47477935)
15. Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci 2009;285:195-197.
16. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 2005;11:101-103. (Pubitemid 40279150)
17. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A double-blind placebocontrolled trial of zonisamide (Zonegran) in the treatment of essential tremor. Mov Disord 2007;22:279-282. (Pubitemid 46374780)
18. Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord 2009;24:437-440.
19. Ceravolo R, Salvetti S, Piccini P, et al. Acute and chronic effects of clozapine in essential tremor. Mov Disord 1999;14:468-472. (Pubitemid 30011658)
20. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003;26:643-659. (Pubitemid 36871837)
21. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. Parkinsonism Relat Disord 2010;16:604-607.